SHUKLA SANJAY (President and CEO) purchased 24.0% of their position (5K shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $33.8K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 1/10/2022ACC: 0001209191-22-002768
Officer· President and CEO
Since Feb 2019
+5K
Net shares
Net buyer
$33.8K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
5K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+5K
Price / share
$6.76
Trade value
$33.81K
% of position
24.0%
1/7/2022
20.80K→25.80K
Total
Net shares
+5K
Net value
$33.81K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/7/2022 | P · Purchase | +5K | $6.76 | $33.81K | 24.0% | 20.80K | 25.80K |
| Total | +5K | $33.81K | ||||||
Derivative Transactions0
No derivative transactions reported